New hope for lymphoma patients: experimental drug TORL-5-700 enters human trials
Disease control
Not yet recruiting
This study tests a new drug, TORL-5-700, in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The trial has two parts: first, finding the safest dose of the drug alone, then testing it in combination with other medicines. About 155 par…
Phase: PHASE1, PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 13, 2026 16:03 UTC